All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.

The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

The Duchenne drug Agamree has started so well in Germany and Austria that the Swiss company is expanding its self-marketing strategy in the top five European markets to include the Nordics, Portugal and Ireland.